The results are not awful, but just don't look substantially better than the standard comparator, which of course has commercial consequences.
Saying that the differences were "not statistically significant because the trial was stopped early and fewer patients were enrolled than originally expected" is a farce.
Why was it stopped early?
Why were more patients not enrolled?
Why wasn't the study done properly?
I'm perplexed that AVX still has a market cap of $125m as of the close today but that might have something to do with liquidity.
Does anyone here remember Metabolic?
AVX has an cash backing adjusted for wind down costs of 2.4c per share...what do you reckon ATC is worth?
Caveat Emptor
Rgds
Prof
AVX Price at posting:
14.5¢ Sentiment: Sell Disclosure: Not Held
